DNA sequences for human tumour suppressor genes

A method for the diagnosis of a predisposition thereto, in a patient, comprising the steps of: (1) establishing the level of expression of a gene selected from the group consisting of PR domain containing 7 protein (PRDM7), CDT1 DNA replication factor (CDT1), charged multivesicular body protein 1/ch...

Full description

Saved in:
Bibliographic Details
Main Authors WHITMORE SCOTT, CALLEN DAVID FREDERICK, POWELL JASON, GARDNER ALISON, KREMMIDIOTIS GABRIEL
Format Patent
LanguageEnglish
Published 02.09.2004
Edition7
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
COMPOSITIONS THEREOF
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROCESSES OF PREPARING SUCH COMPOSITIONS
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:A method for the diagnosis of a predisposition thereto, in a patient, comprising the steps of: (1) establishing the level of expression of a gene selected from the group consisting of PR domain containing 7 protein (PRDM7), CDT1 DNA replication factor (CDT1), charged multivesicular body protein 1/chromoatin modifying protein 1 (CHMP1), BTG3 associated nucleoprotein (BANP), BNO224, BNO36, BNO34, BNO208, BNO230 and BNO44; and (2) comparing expression of the gene to a baseline established from expression in normal tissue controls; wherein substantial variance from the baseline indicates that the patient is susceptible to cancer.
Bibliography:Application Number: US20030467506